Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

@article{Rossouw2002RisksAB,
  title={Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial},
  author={Jacques E Rossouw and Garnet L. Anderson and Ross L Prentice and Andrea Z. LaCroix and Charles L. Kooperberg and Marcia L Stefanick and Rebecca D. Jackson and Shirley A A Beresford and Barbara V. Howard and Karen C Johnson and Jane Morley Kotchen and Judith K. Ockene},
  journal={Obstetrics \& Gynecology},
  year={2002},
  volume={101},
  pages={194}
}
CONTEXT Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. OBJECTIVE To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. DESIGN Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50… 

Figures and Tables from this paper

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
TLDR
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
TLDR
Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.
Estrogen plus progestin, benefits and risks: the "Women's Health Initiative" trials.
  • K. Keller, L. Lemberg
  • Medicine
    American journal of critical care : an official publication, American Association of Critical-Care Nurses
  • 2005
TLDR
Two case presentations highlight key issues involved in hormone replacement therapy in women with significant increased risk of coronary heart disease and the increased requirement for gallbladder surgery.
Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear?
TLDR
No suggestion of a decreased risk for CHD was found within the first 2 years of estrogen plus progestin use, including in women who initiated therapy within 10 years after menopause, and the analysis may not have fully adjusted for joint determinants of adherence and CHD risk.
Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
TLDR
The Women's Health Initiative trial of estrogen plus progestin vs placebo was stopped early, because the overall health risks of hormone therapy exceeded its benefits, indicating that the risks of CEE plus MPA exceed the benefits for chronic disease prevention.
Postmenopausal hormone treatment.
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Estrogen plus progestin and the risk of coronary heart disease.
TLDR
Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.
Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
TLDR
Among postmenopausal women aged 65 years or older, estrogen plus progestin did not improve cognitive function when compared with placebo, and timing of prior hormone therapy initiation with respect to the final menstrual period did not affect the results.
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
TLDR
Estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women, and the mechanisms underlying this higher susceptibility remain to be determined.
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
TLDR
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease, and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
  • Ján
  • Medicine
    JAMA
  • 1995
TLDR
Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure and in women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia.
Effects of Hormone Replacement Therapy on Endometrial Histology in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
TLDR
Combining CEE with cyclic or continuous MPA or cyclic MP protected the endometrium from hyperplastic changes associated with estrogen-only therapy.
A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease
TLDR
The relation among low-dose estrogen, short-term hormone use, and cardiovascular events in 70 533 postmenopausal women with no previous cardiovascular disease who were followed for up to 20 years is examined.
Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS)
TLDR
Hormone therapy with conjugated equine estrogen and progestin had no significant effect on the risk for stroke among postmenopausal women with coronary disease.
Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial
TLDR
1 year of HRT was not effective in slowing progression of subclinical atherosclerosis in postmenopausal women at increased risk, and HRT significantly decreased LDL cholesterol, fibrinogen, and follicle-stimulating hormone.
Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study
TLDR
This study investigated the relation between postmenopausal hormone use and secondary prevention of major coronary events in 2489 women with established coronary disease in the Nurses' Health Study, a large observational cohort.
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
TLDR
Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up, and hormone therapy did not reduce risk of cardiovascular events in women with CHD.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
TLDR
The data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone, and were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease.
...
...